IP Library › Granted Patent US 12,144,812
Granted Patent B2
US 12,144,812 · App. 17/308,376 · Granted Nov 19, 2024

Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

Inventors: Yip-Fong Chia (Menlo Park, CA); Stephen Arboleda (Menlo Park, CA); Yan Alsmeyer (Menlo Park, CA); Gordon Davis (Menlo Park, CA); Tyler Clikeman (Menlo Park, CA)
Assignee: Corcept Therapeutics Incorporated
A61K31/513A61K9/2009A61K9/2013A61K9/2027A61K9/2054A61K9/2095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,144,812
App. No.
17/308,376
Granted
Nov 19, 2024
Kind
B2
Abstract

The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.

Claims (57)

1. A composition comprising:

Compound I, (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione:

in an amount from 20.0 to 28.0% (w/w);

a poly[(methyl methacrylate)-co-(methacrylic acid)] in an amount from 20.0 to 28.0% (w/w);

sodium lauryl sulfate in an amount from 0.5 to 5.0% (w/w);

a sustaining polymer which is hydroxypropyl methylcellulose acetate succinate (HPMCAS), in an amount from 10.0 to 28.0% (w/w);

microcrystalline cellulose in an amount from 10.0 to 25.0% (w/w); and

croscarmellose sodium (Ac-Di-Sol) in an amount from 5.0 to 11.0% (w/w).

2. The composition of claim 1 , wherein the poly[(methyl methacrylate)-co-(methacrylic acid)] has a methyl methacrylate to methacrylic acid ratio of about 1:1.

3. The composition of claim 1 , wherein the sustaining polymer is hydroxypropyl methylcellulose acetate succinate high fine grade (HPMCAS-H).

4. The composition of claim 2 , comprising

Compound I, in an amount from 22.0 to 28.0% (w/w);

the poly[(methyl methacrylate)-co-(methacrylic acid)] having a methyl methacrylate to methacrylic acid ratio of about 1:1, in an amount from 22.0 to 28.0% (w/w);

sodium lauryl sulfate in an amount from 0.5 to 5.0% (w/w)

hydroxypropyl methylcellulose acetate succinate high fine grade in an amount from 13.0 to 28.0% (w/w);

microcrystalline cellulose (Avicel PH102) in an amount from 13.0 to 20.0% (w/w); and

croscarmellose sodium (Ac-Di-Sol) in an amount from 5.0 to 11.0% (w/w).

5. The composition of claim 1 , further comprising sodium lauryl sulfate in an amount from 1.25 to 1.75% (w/w).

6. The composition of claim 1 , further comprising sodium lauryl sulfate in an amount from 1.3 to 1.5% (w/w).

7. The composition of claim 1 , comprising

Compound I, in an amount of about 22.8% (w/w);

the poly[(methyl methacrylate)-co-(methacrylic acid)] having a methyl methacrylate to methacrylic acid ratio of about 1:1, in an amount of about 22.8% (w/w);

sodium lauryl sulfate in an amount of about 1.4% (w/w);

hydroxypropyl methylcellulose acetate succinate high fine grade in an amount of about 23.0% (w/w);

microcrystalline cellulose (Avicel PH102) in an amount of about 19.4% (w/w);

croscarmellose sodium (Ac-Di-Sol) in an amount of about 10.0% (w/w); and

magnesium stearate in an amount of about 0.5% (w/w).

8. The composition of claim 1 , further comprising colloidal silicon dioxide (Cab-O-Sil MP5) in an amount from 0.1 to 2.0% (w/w).

9. The composition of claim 8 , wherein the colloidal silicon dioxide (Cab-O-Sil MP5) is present in an amount from 0.50 to 1.5% (w/w).

10. The composition of claim 1 , comprising

Compound I, in an amount of about 22.8% (w/w);

the poly[(methyl methacrylate)-co-(methacrylic acid)] having a methyl methacrylate to methacrylic acid ratio of about 1:1, in an amount of about 22.8% (w/w);

sodium lauryl sulfate in an amount of about 1.4% (w/w);

hydroxypropyl methylcellulose acetate succinate high fine grade in an amount of about 23.0% (w/w);

microcrystalline cellulose (Avicel PH102) in an amount of about 18.4% (w/w);

croscarmellose sodium (Ac-Di-Sol) in an amount of about 10.0% (w/w);

colloidal silicon dioxide (Cab-O-Sil MP5) in an amount of about 1.0% (w/w); and

magnesium stearate in an amount of about 0.5% (w/w).

11. The composition of claim 8 , wherein the microcrystalline cellulose (Avicel PH102) in an amount from 10.0 to 30.0% (w/w).

12. The composition of claim 11 , wherein the microcrystalline cellulose (Avicel PH102) in an amount from 13.0 to 20.0% (w/w).

13. The composition of claim 11 , wherein the weight ratio of Compound I to the poly[(methyl methacrylate)-co-(methacrylic acid)] is about 1:1.

14. The composition of claim 11 , comprising

Compound I, in an amount of about 25.0% (w/w);

the poly[(methyl methacrylate)-co-(methacrylic acid)] having a methyl methacrylate to methacrylic acid ratio of about 1:1, in an amount of about 25.0% (w/w);

hydroxypropyl methylcellulose acetate succinate high fine grade in an amount of about 25.0% (w/w);

microcrystalline cellulose (Avicel PH102) in an amount of about 13.75% (w/w);

croscarmellose sodium (Ac-Di-Sol) in an amount of about 10.0% (w/w);

colloidal silicon dioxide (Cab-O-Sil MP5) in an amount of about 0.75% (w/w); and

magnesium stearate in an amount of about 0.5% (w/w).

15. The composition of claim 11 , comprising

Compound I, in an amount of about 22.9% (w/w);

the poly[(methyl methacrylate)-co-(methacrylic acid)] having a methyl methacrylate to methacrylic acid ratio of about 1:1, in an amount of about 22.9% (w/w);

hydroxypropyl methylcellulose acetate succinate high fine grade in an amount of about 22.9% (w/w);

microcrystalline cellulose (Avicel PH102) in an amount of about 19.8% (w/w);

croscarmellose sodium (Ac-Di-Sol) in an amount of about 10.0% (w/w);

colloidal silicon dioxide (Cab-O-Sil MP5) in an amount of about 1.0% (w/w); and

magnesium stearate in an amount of about 0.5% (w/w).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2021
From: CHIA, YIP-FONG; ARBOLEDA, STEPHEN; ALSMEYER, YAN
To: CORCEPT THERAPEUTICS INCORPORATED
Reel/Frame 057177/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2021
From: DAVIS, GORDON; CLIKEMAN, TYLER
To: BEND RESEARCH, INC.
Reel/Frame 057177/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2021
From: BEND RESEARCH, INC.
To: CORCEPT THERAPEUTICS INCORPORATED
Reel/Frame 057177/0046 →
Continuity (2)
Provisional Application 63020919 · May 6, 2020
Related Publication 20210361651A1 · Nov 25, 2021
Cited By (1)
US 12,539,290